195 related articles for article (PubMed ID: 18344469)
1. Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage.
Wilson PM; Booth AM; Eastwood A; Watt IS
J R Soc Med; 2008 Mar; 101(3):125-32. PubMed ID: 18344469
[TBL] [Abstract][Full Text] [Related]
2. Demands for 'off-licence' access to trastuzumab (Herceptin): content analysis of UK newspaper articles.
Hind D; Wailoo AJ; Sutcliffe P
Health Expect; 2011 Mar; 14(1):38-47. PubMed ID: 20673243
[TBL] [Abstract][Full Text] [Related]
3. Media influence on Herceptin subsidization in Australia: application of the rule of rescue?
Mackenzie R; Chapman S; Salkeld G; Holding S
J R Soc Med; 2008 Jun; 101(6):305-12. PubMed ID: 18515778
[TBL] [Abstract][Full Text] [Related]
4. How much will Herceptin really cost?
Barrett A; Roques T; Small M; Smith RD
BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
[TBL] [Abstract][Full Text] [Related]
5. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.
Booth CM; Dranitsaris G; Gainford MC; Berry S; Fralick M; Fralick J; Sue J; Clemons M
BMC Cancer; 2007 Jun; 7():110. PubMed ID: 17598896
[TBL] [Abstract][Full Text] [Related]
6. The case of Norplant as an example of media coverage over the life of a new health technology.
Entwistle VA; Watt IS; Johnson F
Lancet; 2000 May; 355(9215):1633-6. PubMed ID: 10821380
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article.
; Burgess EP
N Z Med J; 2006 Jul; 119(1237):U2065; author reply U2065. PubMed ID: 16862207
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital.
Neyt MJ; Albrecht JA; Clarysse B; Cocquyt VF
Int J Technol Assess Health Care; 2005; 21(1):132-7. PubMed ID: 15736525
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab: is the new evidence revolutionary?
Munshi A; Singh P; Jalali R
J Cancer Res Ther; 2006; 2(3):144-6. PubMed ID: 17998695
[TBL] [Abstract][Full Text] [Related]
10. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
Rosevear M
N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.
McKeage K; Lyseng-Williamson KA
Pharmacoeconomics; 2008; 26(8):699-719. PubMed ID: 18620462
[TBL] [Abstract][Full Text] [Related]
12. No such thing as bad publicity? A quantitative content analysis of print media representations of primary care out-of-hours services.
Foster H; Macdonald S; Patterson C; O'Donnell CA
BMJ Open; 2019 Mar; 9(3):e023192. PubMed ID: 30910877
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
Plosker GL; Keam SJ
Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
[TBL] [Abstract][Full Text] [Related]
15. Opinion on the use of the antitumor drug trastuzumab (Herceptin) in patients with metastatic breast cancer in the county Mecklenburg-Vorpommern.
Hehl EM
Int J Clin Pharmacol Ther; 2001 Nov; 39(11):503-6. PubMed ID: 11727972
[TBL] [Abstract][Full Text] [Related]
16. Herceptin and early breast cancer: a moment for caution.
Lancet; 2005 Nov; 366(9498):1673. PubMed ID: 16291043
[No Abstract] [Full Text] [Related]
17. Development and clinical overview of trastuzumab (herceptin).
Frankel C
Semin Oncol Nurs; 2000 Nov; 16(4 Suppl 1):13-7. PubMed ID: 11151453
[TBL] [Abstract][Full Text] [Related]
18. [Reflexion on innovation diffusion factors: the case of Herceptin].
Buron C; Doz M; Salomon AV; Couturier J; Beuzeboc P; Livartowski A
Bull Cancer; 2007 Mar; 94(3):297-306. PubMed ID: 17371772
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab for early breast cancer: evolution or revolution?
Littlejohns P
Lancet Oncol; 2006 Jan; 7(1):22-3. PubMed ID: 16408378
[No Abstract] [Full Text] [Related]
[Next] [New Search]
